Welcome to Morningstar

Type Ticker, Company or Fund Name

Sign Up My Account

Close
Login Log out

Keep me signed in.

Forgot your password?

Not already a member? Click here to register.

Logging in...

Close
Company Site

Shire PLC SHP

Last Price
2,134.00

Day Change
-21.00|-0.97%

As of 23/05/2013
17:14:15 BST | GBX Minimum 15 Minutes Delay.

Bid/Offer	Day Range	Volume	90d Ave Vol	Mkt Cap
2,083.00 - 2,160.00	2,117.00 - 2,161.00	1,905,427	-	11,823.64

Last Close	52 Week Range	P/E	Yield %	ISIN
2,155.00	1,682.00 - 2,173.00	20.98	0.38	JE00B2QKY057

Shire Share Price

more...

Morningstar's Take SHP

Through several acquisitions, Shire has transformed from a neurology-focused specialty pharma to a more diversified firm with exposure to biologics manufacturing and a global marketing strategy. While its business took a hit from generic competition in 2009, we think recent and upcoming product launches will allow Shire to produce high-single-digit top-line growth during the next five years.

Fair Value Estimate

1,745.00 GBX

Uncertainity

Average

Economic Moat

Narrow

Total Returns

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	-0.97
FTSE 100 TR GBP	-2.10

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	6.43
FTSE 100 TR GBP	5.13

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	2.26
FTSE 100 TR GBP	7.03

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	15.70
FTSE 100 TR GBP	32.07

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	17.18
FTSE 100 TR GBP	13.75

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	20.33
FTSE 100 TR GBP	5.84

	Chg (%)
3yr, 5yr & 10yr performance data is annualised.

Shire PLC	18.07
FTSE 100 TR GBP	9.22

Financials
	Annual
	2010	2011	2012
more...
Income Statement
Turnover	2,216.96	2,743.32	2,879.85
Operating Profit	507.19	713.73	583.94
Net Profit	375.55	554.98	457.95
Reported EPS	67.25	97.10	80.53
Balance Sheet
Current Assets	1,200.93	1,420.89	1,976.07
Non Current Assets	2,240.09	2,684.51	2,525.44
Total Assets	3,441.02	4,105.40	4,501.51
Current Liabilities	826.02	1,630.72	1,012.37
Total Liabilities	1,875.33	2,055.98	2,158.11
Total Equity	1,565.69	2,049.42	2,343.40
Cash Flow
Cash From Operations	602.16	690.82	850.75
Change in Net Cash	33.02	44.40	533.74

Broker Forecasts
Year Ending	Pre-tax	EPS	EPSg	P/E	PEG	DPS	Yld %
more...
'Broker Forecasts' provides consensus figures based on several brokers' views
2013	830.06	144.43	41.98	14.78	0.35	11.47	0.54
2014	967.63	165.33	14.47	12.91	0.89	14.06	0.66

Regulatory News

Date	Source	Headline
more...
20/05/13\|12:00	DJ	PRESS RELEASE: Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics(R) For Monogenic Diseases
18/05/13\|03:27	DJ	DJ Holder RUSSELL Registers 32,661 Of SHIRE PLC >SHPG
17/05/13\|15:05	DJ	PRESS RELEASE: Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting

Date	Author	Headline
14/02/2013	Alanna Petroff	FTSE Falls from 5-Year High THURSDAY MARKET UPDATE: Shire and AMEC contribute to a 0.5% decline on the FTSE 100, ending a four-day market rally
29/11/2011	Holly Cook	Shire Shares Overvalued After Rally Morningstar Equity Research implies the market is overvaluing the pharma stock relative to its fair value
09/11/2011	Karen Andersen, CFA	Raising Our Fair Value Estimate for Shire Shire's 3Q was in line with our expectations but we're boosting our fair value estimate on ADHD potential and Sanofi's extended Fabrazyme shortages

Director Dealings
Traded	Action	Notifier	Price	Amount	Value
more...
02/04/2013	Sale	Angus Russell	2004.03	18,528	371,306.00
02/04/2013	Exercise of Option	Angus Russell	0.00	22,263	0.00
02/04/2013	Sale	Graham Hetherington	1994.00	6,552	130,647.00
02/04/2013	Exercise of Option	Graham Hetherington	0.00	12,569	0.00

Company Profile

Shire PLC is a biopharmaceutical company. It focuses on meeting the needs of specialist physicians. The Company's activities include research and development, manufacture, sale and distribution of pharmaceutical products.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Large-Growth

Fiscal Year Ends

December

Employees

5367

Outlook

(02/05/2013) "...we continue to expect to deliver earnings growth in line with current consensus earnings expectations for 2013"

Next Event 01/08/2013

Next interim announcement

Ratios
	Comp	Sec	Mkt

PER (E)	13.99	13.34	13.93
Div Yld (E)	0.59	4.77	3.73
PEG (E)	0.48	-0.37	0.25
ROCE	48.14	51.40	-20.93
Op Mrgn	24.59	20.65	-54.21
EPS Grwth	28.92	14.65	16.34

Dividends
	Previous	Latest
more...
Declared Date	07/09/12	08/03/13
Ex-Div	05/09/12	06/03/13
Paid	04/10/12	09/04/13
Amnt p	1.74	9.39

Broker Forecasts

Strong Buy	0
Buy	4
Hold	0
Sell	1
Strong Sell	0

Strong Sell
Strong Buy